Appendix B, Table 6. Characteristics of Integrase Strand Transfer Inhibitors
(Last updated June 3, 2021; last reviewed June 3, 2021) (page 1 of 4)

Generic Name (Abbreviation) *Trade Name*	Formulations	Dosing Recommendations[a]	Elimination/ Metabolic Pathways	Serum Half-Life	Adverse Events[b]
Bictegravir (BIC)	BIC is available only as a component of the STR Biktarvy (BIC/TAF/FTC).[c]	**Biktarvy:** • One tablet PO once daily	CYP3A4 substrate UGT1A1-mediated glucuronidation	~17 hours	Diarrhea Nausea Headache Weight gain
Cabotegravir (CAB)	Available as part of the copackaged intramuscular long-acting regimen Cabenuva (CAB IM and RPV IM): • 400-mg/2-mL vial • 600-mg/3-mL vial Also available in oral tablet formulation Vocabria (CAB PO): • 30-mg tablet • Must be obtained from manufacturer for oral lead-in and oral bridging during administration of Cabenuva (CAB IM/RPV IM)	See Appendix B, Table 1 for dosing information for coformulated and copackaged regimens that contain CAB.	UGT1A1 and UGT1A9-mediated glucuronidation	Oral: 41 hours IM: 6–12 weeks	Headache Nausea Abnormal dreams Anxiety Insomnia Depressive disorders Hepatotoxicity IM formulation only: Injection-site reactions (e.g., pain, induration, swelling, nodules)

Appendix B, Table 6. Characteristics of Integrase Strand Transfer Inhibitors
(Last updated June 3, 2021; last reviewed June 3, 2021) (page 2 of 4)

Generic Name (Abbreviation) *Trade Name*	Formulations	Dosing Recommendations[a]	Elimination/ Metabolic Pathways	Serum Half-Life	Adverse Events[b]
Dolutegravir (DTG) *Tivicay*	**Tivicay:** • 10 mg, 25 mg, and 50 mg tablets • 5 mg soluble tablet **STRs that Contain DTG:**[c] • Dovato (DTG/3TC) • Juluca (DTG/RPV) • Triumeq (DTG/ABC/3TC)	**In ARV-Naive or ARV-Experienced, INSTI-Naive Patients:** • DTG 50 mg PO once daily **In ARV-Naive or ARV-Experienced, INSTI-Naive Patients when Coadministered with EFV, FPV/r, TPV/r, or Rifampin:** • DTG 50 PO mg twice daily **INSTI-Experienced Patients with Certain INSTI Mutations (See Product Label) or with Clinically Suspected INSTI Resistance:** • DTG 50 mg PO twice daily See Appendix B, Table 1 for dosing information for STRs that contain DTG.	UGT1A1-mediated glucuronidation Minor substrate of CYP3A4	~14 hours	Insomnia Headache Depression and suicidal ideation (rare; usually occurs in patients with preexisting psychiatric conditions) Weight gain Hepatotoxicity Potential for increased risk of NTDs in infants born to individuals who received DTG around the time of conception is lower than previously reported. Refer to INSTI section for more information. HSRs, including rash, constitutional symptoms, and organ dysfunction (including liver injury), have been reported.

Appendix B, Table 6. Characteristics of Integrase Strand Transfer Inhibitors
(Last updated June 3, 2021; last reviewed June 3, 2021) (page 3 of 4)

Generic Name (Abbreviation) *Trade Name*	Formulations	Dosing Recommendations[a]	Elimination/ Metabolic Pathways	Serum Half-Life	Adverse Events[b]
Elvitegravir (EVG)	EVG is only available as a component of an STR tablet that also contains COBI, FTC, and either TDF or TAF. **STRs that Contain EVG:**[c] • Genvoya (EVG/c/TAF/FTC) • Stribild (EVG/c/TDF/FTC)	**Genvoya:** • One tablet PO once daily with food • See Appendix B, Table 11 for recommendations on dosing in persons with renal insufficiency. **Stribild:** • One tablet PO once daily with food • **Not recommended** for patients with baseline CrCl <70 mL/min (see Appendix B, Table 11 for the CrCl calculation equation).	**EVG:** • CYP3A and UGT1A1/3 substrate **COBI:** • CYP3A inhibitor and substrate • CYP2D6 inhibitor	**EVG/c:** ~13 hours	Nausea Diarrhea Depression and suicidal ideation (rare; usually occurs in patients with preexisting psychiatric conditions)
Raltegravir (RAL) *Isentress* *Isentress HD*	**Isentress:** • 400-mg tablet • 25-mg and 10-mg chewable tablets • 100-mg single-use packet for oral suspension **Isentress HD:** • 600-mg tablet	**Isentress** *In ARV-Naive Patients or ARV-Experienced Patients:* • 400 mg PO twice daily *With Rifampin:* • 800 mg PO twice daily **Isentress HD** *In ARV-Naive or ARV-Experienced Patients with Virologic Suppression on a Regimen containing RAL 400 mg Twice Daily:* • 1,200 mg (two 600-mg tablets) PO once daily *With Rifampin:* • **Not recommended**	UGT1A1-mediated glucuronidation	~9 hours	Rash, including Stevens-Johnson syndrome, HSR, and toxic epidermal necrolysis Nausea Headache Diarrhea Pyrexia CPK elevation, muscle weakness, and rhabdomyolysis

Appendix B, Table 6. Characteristics of Integrase Strand Transfer Inhibitors
(Last updated June 3, 2021; last reviewed June 3, 2021) (page 4 of 4)

Generic Name (Abbreviation) *Trade Name*	Formulations	Dosing Recommendations[a]	Elimination/ Metabolic Pathways	Serum Half-Life	Adverse Events[b]
Raltegravir (RAL) *Isentress Isentress HD continued*					Weight gain Insomnia Depression and suicidal ideation (rare; usually occurs in patients with preexisting psychiatric conditions)

[a] For dose adjustments in patients with hepatic insufficiency, see Appendix B, Table 11. When no food restriction is listed, the ARV drug can be taken with or without food.

[b] Also see Table 20.

[c] See Appendix B, Table 1 for information about these formulations.

Key: 3TC = lamivudine; ABC = abacavir; ARV = antiretroviral; BIC = bictegravir; CAB = cabotegravir; COBI = cobicistat; CPK = creatine phosphokinase; CrCl = creatinine clearance; CYP = cytochrome P; DTG = dolutegravir; EFV = efavirenz; EVG = elvitegravir; EVG/c = elvitegravir/cobicistat; FPV/r = fosamprenavir/ritonavir; FTC = emtricitabine; HSR = hypersensitivity reaction; IM = intramuscular; INSTI = integrase strand transfer inhibitor; NTD = neural tube defect; PO = orally; RAL = raltegravir; RPV = rilpivirine; STR = single-tablet regimen; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate; TPV/r = tipranavir/ritonavir; UGT1 = uridine diphosphate glucuronyl transferase 1 family